ue2343
Small moleculeexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT01770886)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
HSD11B1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ue2343
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04983368 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2021 | Actinogen Medical, Avance Clinical Pty Ltd. |
| NCT02616445 | Phase 1 | Feb 1, 2015 | Actinogen Medical, Linear Clinical Research, Novotech |
| NCT01770886 | Phase 1 | Jan 1, 2013 | Simbec-Orion, University of Edinburgh, Wellcome Trust |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Actinogen Medical | For profit | 2 | 2 | 2 | 2015 |
| Avance Clinical Pty Ltd. | For profit | 1 | 0 | 1 | 2021 |
| Linear Clinical Research | For profit | 1 | 0 | 1 | 2015 |
| Novotech | For profit | 1 | 0 | 1 | 2015 |
| Simbec-Orion | For profit | 1 | 0 | 1 | 2013 |
| University of Edinburgh | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2013 |
7 organizations
Page 1 / 1